All In Biotech

Drug Trial Radar · NCT02655315

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"

Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

372

Actual

Start

Feb 9, 2016

Primary completion

Sep 22, 2020

Study completion Sep 22, 2020

Sponsor

Lead sponsor
University Hospital, LilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission; ApoPharma
First posted
Jan 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.

Conditions

  • Parkinson Disease

Interventions

  • DeferiproneDrug

    15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.

  • PlaceboDrug

    the placebo twice daily morning and evening. The treatment lasts nine months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global effect (symptomatic and disease modifying effects) on motor and non motor handicapTime frame: at 36 weeks

Locations

25 sites in 8 countries. Site status is shown where the registry gives one.

  • Medizinische Universitat Innsbruck

    Innsbruck, Austria

  • Charles University

    Prague, Czechia

  • Univerzita Karlova V Praze

    Prague, Czechia

  • CHU Pellegrin

    Bordeaux, France

  • Hôpital Wertheimer

    Bron, France

  • Hôpital Montpied

    Clermont-Ferrand, France

  • Hôpital Salengro, CHRU

    Lille, France

  • CHU la TIMONE

    Marseille, France

  • AP-HP, Hôpital Pitié-Salpêtrière

    Paris, France

  • CHU de Strasbourg, Hôpital de Hautepierre

    Strasbourg, France

  • Chu Purpan

    Toulouse, France

  • University Hospital, Saarland University

    Homburg, Germany

  • Christian-albrechts universität zu kiel

    Kiel, Germany

  • Klinik und Poliklinik für Neurologie der Universitätsmedizin Rostock

    Rostock, Germany

  • Acadamic central center, Amsterdam

    Amsterdam, Netherlands

  • Radboud university medical center

    Nijmegen, Netherlands

  • Centro Hospitalar e universitario de Coimbra

    Coimbra, Portugal

  • Centro Hospitalar do Alto Ave

    Guimarães, Portugal

  • Centro Hospitalar Lisboa Norte

    Lisbon, Portugal

  • Hospital Clinic Universitari de Barcelona

    Barcelona, Spain

  • Hospital de Bellvitge

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Cambridge University Hospital

    Cambridge, United Kingdom

  • University of Glasgow

    Glasgow, United Kingdom

  • Newcastle University

    Newcastle, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.